ghk cu injectable safety adverse events GHK-Cu Peptide FDA scientists flag concerns with

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition

Technical Characteristics Compound name: BPC-157 Full designation: Body Protection Compound-157 Type: Synthetic peptide Form: Lyophilized powder Purity: 98% Regulatory status: Research Use Only (RUO) Classification: Not intended for clinical, therapeutic, or diagnostic use Each batch is tested to ensure identity, purity, and consistency, ensuring reliability in scientific research applications

1 and Supplementary Tables 1 and 2)

However, these methods require more technical support, such as the MTR was limited with the spatial resolution and less reproducibility 29 , which is also one of the goals of our further research